EQUILLIUM INC (EQ) Stock Price, Quote, News and Overview
NASDAQ:EQ - Nasdaq - US29446K1060 - Common Stock - Currency: USD
EQ Quote, Performance and Key Statistics
0.93
0 (-0.44%)
The current stock price of EQ is 0.93 USD. In the past month the price increased by 124.15%. In the past year, price increased by 18.46%.
EQ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.02 | 355.88B | ||
| AMGN | AMGEN INC | 13.27 | 155.58B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 149.45B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.37 | 101.67B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 60.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 56.40B | ||
| ARGX | ARGENX SE - ADR | 69.75 | 39.57B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.68 | 33.28B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.11B | ||
| INSM | INSMED INC | N/A | 23.31B | ||
| NTRA | NATERA INC | N/A | 21.53B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.96B |
Related stock screener links
About EQ
Company Profile
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 35 full-time employees. The company went IPO on 2018-10-12. The company is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.
Company Info
EQUILLIUM INC
2223 Avenida de La Playa Ste 105
La Jolla CALIFORNIA 92037 US
CEO: Bruce D. Steel
Employees: 35
Phone: 18584125302
EQUILLIUM INC / EQ FAQ
What is the stock price of EQUILLIUM INC today?
The current stock price of EQ is 0.93 USD. The price decreased by -0.44% in the last trading session.
What is the ticker symbol for EQUILLIUM INC stock?
The exchange symbol of EQUILLIUM INC is EQ and it is listed on the Nasdaq exchange.
On which exchange is EQ stock listed?
EQ stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EQUILLIUM INC stock?
10 analysts have analysed EQ and the average price target is 1.02 USD. This implies a price increase of 9.68% is expected in the next year compared to the current price of 0.93. Check the EQUILLIUM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EQUILLIUM INC worth?
EQUILLIUM INC (EQ) has a market capitalization of 33.22M USD. This makes EQ a Nano Cap stock.
How many employees does EQUILLIUM INC have?
EQUILLIUM INC (EQ) currently has 35 employees.
What are the support and resistance levels for EQUILLIUM INC (EQ) stock?
EQUILLIUM INC (EQ) has a support level at 0.53 and a resistance level at 0.94. Check the full technical report for a detailed analysis of EQ support and resistance levels.
Is EQUILLIUM INC (EQ) expected to grow?
The Revenue of EQUILLIUM INC (EQ) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EQ EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EQUILLIUM INC (EQ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EQ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EQ, evaluating the profitability, health, valuation and growth aspects
- EQUILLIUM INC (EQ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EQUILLIUM INC (EQ) Sales and EPS estimates to see what analysts future expectations are.
- EQUILLIUM INC (EQ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EQUILLIUM INC (EQ) Insider and Institutional Ownership to learn about the owners and their transactions.
- EQUILLIUM INC (EQ) Stock Chart to make your own analysis
- EQUILLIUM INC (EQ) Latest news and press-releases to stay up to date.
Does EQUILLIUM INC (EQ) stock pay dividends?
EQ does not pay a dividend.
When does EQUILLIUM INC (EQ) report earnings?
EQUILLIUM INC (EQ) will report earnings on 2025-11-11.
What is the Price/Earnings (PE) ratio of EQUILLIUM INC (EQ)?
EQUILLIUM INC (EQ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
What is the Short Interest ratio of EQUILLIUM INC (EQ) stock?
The outstanding short interest for EQUILLIUM INC (EQ) is 4.01% of its float. Check the ownership tab for more information on the EQ short interest.
EQ Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EQ. When comparing the yearly performance of all stocks, EQ is one of the better performing stocks in the market, outperforming 95.79% of all stocks.
EQ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EQ. EQ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
EQ Financial Highlights
Over the last trailing twelve months EQ reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS decreased by -8.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.61% | ||
| ROE | -132.23% | ||
| Debt/Equity | 0 |
EQ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 42% to EQ. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -280.65% and a revenue growth -100% for EQ